form8k080107.htm
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event
reported) August 1,
2007
PROTOKINETIX,
INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
000-32917
|
|
94-3355026
|
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
|
of
Incorporation)
|
|
|
|
Identification
Number)
|
| |
|
Suite
1500-885 West Georgia Street
|
|
|
| |
|
Vancouver,
British Columbia
|
|
|
| |
|
V6C
3E8
|
|
|
| |
|
(Address
of principal executive offices)
|
|
|
| |
|
|
|
|
| |
|
604-687-9887
|
|
|
| |
|
(Registrant’s
Telephone Number)
|
|
|
_____________________________________________________________________________________
(Former
name or former
address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section
5 – Corporate Governance and Management
Item
5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On
August
1, 2007, Mark L. Baum, Esq. resigned from his position as Director and interim
President of ProtoKinetix, Inc. (the “Corporation”). Mr. Baum’s
resignation was not because of any disagreements with the Corporation on matters
relating to its operations, policies, disclosures and/or practices.
On
August
1, 2007, our Board of Director appointed Dr. Maximilien Arella to the position
of Director.
Dr.
Maximilien Arella, PhD
Dr.
Arella is one of our Directors. He is not a full time employee and has other
outside commitments. For the past twenty years, Dr. Arella has acted as a
private consultant advising clients and businesses with technological and
scientific development, innovative technology transfer and commercial
development from university benchtop to commercial developments.
Since
1993, Dr. Arella has carried out two mandates as chairman of the Virology
Research Center of the Armand-Frappier Institute/University of Quebec (the
“IAF”) during which he held the responsibility of managing both the research and
the teaching programs (M.Sc. and Ph.D.) consisting of a team of 20 researchers
combined with approximately 100 students and support employees. From 1984 to
1993 Dr. Arella was scholar, assistant professor and professor of Virology
at
IAF as well as adjunct professor at the School of Graduate Studies of the
University of Montreal. He also served as president of the professor
association from 1989 to 1992. His academic research is mainly based in the
fields of molecular biology, fundamental aspects and applications of the
double-stranded RNA virus, as well as amplification systems for the analysis
of
human and animal viruses, and cancer markers. Throughout his career, he has
written 76 scientific publications, 24 scientific reports for research contracts
as well as 28 chapters in books and summaries of techniques. He has been invited
to give 49 conferences, has presented 198 scientific communications and has
submitted 3 patents. Mr. Arella is fluent in English, French and
Italian.
In
addition to his position with ProtoKinetix, Dr. Arella sits on the scientific
advisory boards of two addition publicly traded companies, Biophage, Inc. and
Viropro, Inc.
On
August
1, 2007, our Board of Directors appointed Mr. Ross L. Senior to the positions
of
President and Chief Executive Officer.
Mr.
Ross L. Senior
Mr.
Senior is our President and Chief Executive Officer. In 2005, Mr. Senior
co-founded Rowan All Natural Skin Care, Inc., a Canadian-based provider of
skin
care products. In 1988, Mr. Senior founded Ross L. Senior and Associates, a
business consulting firm, where he maintained his position as principal of
the
firm from 1988 to 2005. Mr. Senior brings to ProtoKinetix a combination of
business, organizational and legal experience through consultation roles in
technology research and development institutions and a wide range of businesses
including health care, property development, electronics distribution,
manufacturing, natural resources, educational institutions and social
enterprises.
Section
9 – Financial Statements and Exhibits
Item
9.01 Financial
Statements and Exhibits.
(c) Exhibits.
|
Number
|
|
Description
|
| |
|
|
|
99.1
|
|
Resignation
letter of Mark L. Baum, Esq.
|
| |
|
|
|
99.2
|
|
Acceptance
letter of Dr. Maximilien Arella, PhD
|
| |
|
|
|
99.3
|
|
Acceptance
letter of Ross L. Senior
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
|
|
PROTOKINETIX,
INC.
|
|
|
/s/
|
Ross
L. Senior
______________
|
|
|
By:
|
Ross
L. Senior
|
|
|
Its:
|
President
and Chief Executive Officer
|